SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy

Yawen WANG,Ismail Meraz,Md Qudratullah,Sasikumar Kotagiri,Yanyan Han,Yuanxin Xi,Jing Wang,Yonathan Lissanu

DOI: https://doi.org/10.1101/2024.06.18.599431

2024-06-22

Abstract:Cancer genomic studies have identified frequent alterations in components of the SWI/SNF (SWItch/Sucrose Non- Fermenting) chromatin remodeling complex including SMARCA4 and ARID1A. Importantly, clinical reports indicate that SMARCA4-mutant lung cancers respond poorly to immunotherapy and have dismal prognosis. However, the mechanistic basis of immunotherapy resistance is unknown. Here, we corroborated the clinical findings by using immune-humanized, syngeneic, and genetically engineered mouse models of lung cancer harboring SMARCA4 deficiency. Specifically, we show that SMARCA4 loss caused decreased response to anti-PD1 immunotherapy associated with significantly reduced infiltration of dendritic cells (DCs) and CD4+ T cells into the tumor microenvironment (TME) . Mechanistically, we show that SMARCA4 loss in tumor cells led to profound downregulation of STING, IL1β and other components of the innate immune system as well as inflammatory cytokines that are required for efficient recruitment and activity of immune cells. We establish that this deregulation of gene expression is caused by cancer cell-intrinsic reprogramming of the enhancer landscape with marked loss of chromatin accessibility at enhancers of genes involved in innate immune response such as STING, IL1β, type I IFN and inflammatory cytokines. Interestingly, we observed that transcription factor NF-κB binding motif was highly enriched in enhancers that lose accessibility upon SMARCA4 deficiency. Finally, we confirmed that SMARCA4 and NF-κB co-occupy the same genomic loci on enhancers associated with STING and IL1β, indicating a functional interplay between SMARCA4 and NF-κB. Taken together, our findings provide the mechanistic basis for the poor response of SMARCA4-mutant tumors to anti-PD1 immunotherapy and establish a functional link between SMARCA4 and NF-κB on innate immune and inflammatory gene expression regulation.

Immunology

What problem does this paper attempt to address?

The problem this paper attempts to address is: **How SMARCA4 mutations lead to intrinsic defects in tumor cells, causing resistance to immunotherapy**.

Specifically, researchers found that lung cancer with SMARCA4 mutations responds poorly to immunotherapy and has a worse prognosis. However, the underlying mechanisms are unclear. This paper explores how SMARCA4 loss leads to reduced infiltration of dendritic cells (DCs) and CD4+ T cells in the tumor microenvironment through various experimental models (such as immune-humanized mouse models, syngeneic models, and genetically engineered mouse models), thereby explaining the molecular mechanisms of resistance to immunotherapy in SMARCA4-mutant tumors.

The main findings include:
1. **SMARCA4 loss leads to decreased response to PD-1 immunotherapy**: In multiple experimental models, tumors with SMARCA4 loss showed a significantly reduced response to PD-1 antibody treatment.
2. **Reduced immune cell infiltration**: Tumors with SMARCA4 loss had significantly reduced infiltration of DCs and CD4+ T cells.
3. **Abnormal regulation of gene expression**: SMARCA4 loss led to a significant downregulation of genes related to the innate immune system, such as STING and IL1β, which are crucial for the effective recruitment and activation of immune cells.
4. **Reprogramming of enhancer landscape**: SMARCA4 loss resulted in a significant decrease in chromatin accessibility at enhancer regions, particularly those related to genes involved in the innate immune response.
5. **Functional interaction between SMARCA4 and NF-κB**: SMARCA4 and NF-κB co-occupy enhancers associated with genes like STING and IL1β, indicating a functional interaction between them.

In summary, this paper reveals the molecular mechanisms of resistance to immunotherapy in SMARCA4-mutant tumors, providing a theoretical basis for developing new therapeutic strategies.